New hope for liver cancer: drug combo targets tumors after immunotherapy fails
NCT ID NCT07238881
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether combining dalpiciclib (a CDK4/6 inhibitor) with camrelizumab (an immunotherapy) can shrink tumors in 30 people with advanced liver cancer that progressed after prior immunotherapy. The study aims to find a new second-line option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULCAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dalpiciclib and camrelizumab
What this could lead to
If it works, this could offer a new second-line treatment option for people with advanced liver cancer who have already tried immunotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.